While the basic course is free and great for getting started, they also have a ‘Pro’ version if you want to dig deeper. It’s a solid choice if you’re totally new to programming and want a smooth, ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

OpenAI is testing a new model for Codex called "GPT-5.2-Codex-Max." Some users have spotted a new model, GPT-5.2-Codex-Max, when they ask Codex what model it is using. OpenAI rolled out Codex with GPT ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

What if the future of artificial intelligence wasn’t just about incremental improvements but a complete redefinition of what’s possible? Enter GPT 5.2, the AI model that has shattered expectations and ...

What if the future of work wasn’t just faster, but smarter, effortlessly blending creativity, technical precision, and strategic insight? OpenAI’s latest release, ChatGPT 5.2, promises to redefine ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Developer AI coding tool Cursor continues to gobble up venture capital as its valuation keeps climbing. On Thursday, Cursor announced a $2.3 billion funding round that valued the company at $29.3 ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...